WO2015047072A1 - Ensemble multiplex d'anticorps spécifiques pour le pronostic, la détection et la surveillance du processus de fibrogenèse. - Google Patents

Ensemble multiplex d'anticorps spécifiques pour le pronostic, la détection et la surveillance du processus de fibrogenèse. Download PDF

Info

Publication number
WO2015047072A1
WO2015047072A1 PCT/MX2014/000148 MX2014000148W WO2015047072A1 WO 2015047072 A1 WO2015047072 A1 WO 2015047072A1 MX 2014000148 W MX2014000148 W MX 2014000148W WO 2015047072 A1 WO2015047072 A1 WO 2015047072A1
Authority
WO
WIPO (PCT)
Prior art keywords
spheres
biomarkers
specific
antibodies
igfbp
Prior art date
Application number
PCT/MX2014/000148
Other languages
English (en)
Spanish (es)
Inventor
Esperanza Gabriela GUTIÉRREZ REYES
David KERSHENOBICH STALNIKOWITZ
Original Assignee
Universidad Nacional Autónoma de México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Nacional Autónoma de México filed Critical Universidad Nacional Autónoma de México
Publication of WO2015047072A1 publication Critical patent/WO2015047072A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Definitions

  • Fibrosis is a finding in multiple progressive diseases, which can affect different organs, such as the liver, pancreas, lung, heart and kidney, so it constitutes a major morbidity and mortality problem at the level worldwide as it is a scar response to different etiological agents such as alcoholism, chronic viral hepatitis and non-alcoholic liver disease.
  • the biopsy Despite its high sensitivity and specificity, the biopsy has disadvantages.
  • the first is that it is an invasive procedure that represents a potential risk, because patients with cirrhosis do not produce clotting factors normally, which increases the likelihood of bleeding, and it is difficult to take Sufficient tissue samples to properly monitor the disease.
  • proteomic methods are not used as a diagnostic method, instead, they are used in the identification of potential biomarkers that can be validated and quantified in an accessible way to constitute new non-invasive diagnostic methods.
  • Figures 5A and 5B refer to the graphs showing the coupling validation of the chemokine detection antibody CXCL-7.
  • Figures 6A and 6B refer to the graphs showing the coupling validation of the chemokine detection antibody CXCL-9.
  • the multiplex assay is carried out using standard curves of eight concentrations obtained by serial dilutions, in which the labeled spheres are placed plus the corresponding standard and incubated with stirring, washing and adding the biotinylated detection antibody, subsequently incubate, wash and add a streptavidin-PE solution, the samples are incubated with stirring and washed and then resuspended in phosphate buffer solution, shake and read on the BIOPLEX equipment.
  • Figures 11A, 11B and 11C show the linearity plot for the multiple assay with the spheres for CXCL-7, CXCL-9 and IGFBP-1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des marqueurs biologiques non invasifs couplés à des sphères fonctionnant comme supports solides dans un ensemble multiplex, et qui sont utiles pour la détection, le pronostic et la surveillance du processus de fibrogenèse.
PCT/MX2014/000148 2013-09-24 2014-09-24 Ensemble multiplex d'anticorps spécifiques pour le pronostic, la détection et la surveillance du processus de fibrogenèse. WO2015047072A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2013/010938 2013-09-24
MX2013010938A MX356444B (es) 2013-09-24 2013-09-24 Arreglo múltiple de anticuerpos específicos para el pronóstico, detección y vigilancia del proceso fibrogénico.

Publications (1)

Publication Number Publication Date
WO2015047072A1 true WO2015047072A1 (fr) 2015-04-02

Family

ID=52744064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000148 WO2015047072A1 (fr) 2013-09-24 2014-09-24 Ensemble multiplex d'anticorps spécifiques pour le pronostic, la détection et la surveillance du processus de fibrogenèse.

Country Status (2)

Country Link
MX (1) MX356444B (fr)
WO (1) WO2015047072A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073822A2 (fr) * 2002-02-28 2003-09-12 Prometheus Laboratories, Inc. Procedes de diagnostic de fibrose hepatique
ES2259291T3 (es) * 2000-08-21 2006-10-01 Assistance Publique, Hopitaux De Paris Metodo de diagnostico de enfermedad fibrotica que utiliza marcadores bioquimicos.
ES2282780T3 (es) * 2004-08-12 2007-10-16 F. Hoffmann-La Roche Ag Metodo para el diagnostico de la fibrosis hepatica.
ES2366123T3 (es) * 2004-10-30 2011-10-17 F. Hoffmann-La Roche Ag Método para la determinación de anticuerpos de una clase específica utilizando un anticuerpo inmunocomplejo específico.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259291T3 (es) * 2000-08-21 2006-10-01 Assistance Publique, Hopitaux De Paris Metodo de diagnostico de enfermedad fibrotica que utiliza marcadores bioquimicos.
WO2003073822A2 (fr) * 2002-02-28 2003-09-12 Prometheus Laboratories, Inc. Procedes de diagnostic de fibrose hepatique
ES2282780T3 (es) * 2004-08-12 2007-10-16 F. Hoffmann-La Roche Ag Metodo para el diagnostico de la fibrosis hepatica.
ES2366123T3 (es) * 2004-10-30 2011-10-17 F. Hoffmann-La Roche Ag Método para la determinación de anticuerpos de una clase específica utilizando un anticuerpo inmunocomplejo específico.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRAUNERSREUTHER V ET AL.: "Role of cytokines and chemokines in non-alcoholic fatty liver disease.", WORLD JOURNAL OF GASTROENTEROLOGY., vol. 18, no. 8, 2012, pages 727 - 735 *

Also Published As

Publication number Publication date
MX356444B (es) 2018-05-21
MX2013010938A (es) 2015-03-24

Similar Documents

Publication Publication Date Title
ES2792227T3 (es) Predicción de evento de riesgo cardiovascular y usos de la misma
Langley et al. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques
ES2777002T3 (es) Predicción de eventos de riesgo cardiovascular y usos de la misma
Atiakshin et al. Characterization of mast cell populations using different methods for their identification
KR101678703B1 (ko) 갈렉틴-３ 면역검정
ES2674570T3 (es) MCAM como un biomarcador para la homeostasis de líquidos
ES2868077T3 (es) Diagnóstico mediante células tumorales circulantes para biomarcadores predictivos de la resistencia a las terapias selectivas del receptor de andrógenos (RA)
JP6018923B2 (ja) 敗血症の予後の予測方法
KR20160045547A (ko) 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
US10613090B2 (en) Methods of detecting cancer
ES2869866T3 (es) Diagnóstico mediante células tumorales circulantes para la identificación de la resistencia a las terapias selectivas del receptor de andrógenos
CN103429757A (zh) 癌症诊断和治疗
Tsuda HER-2 (c-erbB-2) test update: present status and problems
CN109868315A (zh) 用于早期检测脑动脉瘤性蛛网膜下腔出血严重程度及预后的体外方法
Paleari et al. Osteopontin is not a specific marker in malignant pleural mesothelioma
ES2306080T3 (es) Procedimiento para el diagnostico de septicemina mediante determinacion selectiva de la concentracion de superoxidodismutasa cu/zn (sod cu/zn) en muestras de pacientes.
Roura et al. Extracellular vesicles do not contribute to higher circulating levels of soluble LRP 1 in idiopathic dilated cardiomyopathy
WO2015047072A1 (fr) Ensemble multiplex d'anticorps spécifiques pour le pronostic, la détection et la surveillance du processus de fibrogenèse.
US20150118224A1 (en) Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof
Pérez-Carrillo et al. Alpha-cardiac actin serum expression levels detect acute cellular rejection in heart transplant patients
ES2599818T3 (es) Uso de la forma soluble de AXL en el diagnóstico y/o pronóstico de síndrome de insuficiencia cardíaca
CN108026584A (zh) 非小细胞肺癌诊断用蛋白质生物标志物组及利用其的非小细胞肺癌诊断方法
Chen et al. Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis
KR101247636B1 (ko) 편평상피세포암의 진단용 마커 및 이를 포함한 키트
Zencir et al. Fibulin‑1 and fibulin‑5 as rule‑out tests for non–ST‑elevation myocardial infarction in the emergency setting

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14848726

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14848726

Country of ref document: EP

Kind code of ref document: A1